Groupama Asset Managment Has $6.77 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Groupama Asset Managment increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 7.6% in the 4th quarter, HoldingsChannel reports. The firm owned 103,424 shares of the biotechnology company’s stock after acquiring an additional 7,340 shares during the period. Groupama Asset Managment’s holdings in BioMarin Pharmaceutical were worth $6,769,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in BMRN. Vanguard Group Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company’s stock worth $1,273,334,000 after buying an additional 93,531 shares in the last quarter. Norges Bank acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at $234,645,000. Geode Capital Management LLC boosted its stake in BioMarin Pharmaceutical by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 3,288,778 shares of the biotechnology company’s stock worth $215,784,000 after acquiring an additional 28,728 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in BioMarin Pharmaceutical by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,423,508 shares of the biotechnology company’s stock worth $93,567,000 after acquiring an additional 21,880 shares in the last quarter. Finally, abrdn plc grew its holdings in BioMarin Pharmaceutical by 31.9% in the fourth quarter. abrdn plc now owns 695,802 shares of the biotechnology company’s stock worth $45,735,000 after purchasing an additional 168,121 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,295 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the sale, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. This trade represents a 7.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $67.94 on Wednesday. The business’s fifty day simple moving average is $67.75 and its 200 day simple moving average is $67.30. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The firm has a market capitalization of $12.96 billion, a P/E ratio of 30.88, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on BMRN shares. Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a research report on Thursday, February 20th. Bank of America upped their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. UBS Group raised their price objective on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a “sector perform” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.